The accuracy of patient reports of a family history of cancer

Love, Richard R.; Evans, Alida M.; Josten, Denise M.

doi:10.1016/0021-9681(85)90074-8

Cited by 227 publications

(100 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only a few studies have addressed the accuracy of the family's record of cancer, mainly when it was collected for epidemiological purposes. [1][2][3][4][5][6][7][8][9][10][11] Studies on the accuracy of a family's history of cancer as obtained by methods commonly used in family cancer clinics are rare 12,13 In this retrospective study we investigated the accuracy of the family's history of cancer, in the setting of the familial cancer clinic in Groningen.…”

Section: Introductionmentioning

confidence: 99%

Accuracy of family history of cancer: clinical genetic implications

et al. 2000

View full text Add to dashboard Cite

Family medical history is the cornerstone of clinical genetic diagnosis and management in cases of familial cancer. The soundness of medical decisions can be compromised if reports by the family on affected relatives are inaccurate. Although very time consuming, family medical histories are therefore routinely verified. To investigate whether such verification is clinically justified, we retrospectively analysed the accuracy of a consecutive series of 383 tumour reports from counsellees on 120 families in our clinic. We evaluated these families for the impact of verification on clinical genetic diagnosis and management. Accuracy according to cancer type showed marked variation, ranging from 93% and 89% for breast cancer and colorectal cancer, respectively, to 42% and 37% for extra-colorectal alimentary tract cancer and uterine cancer. Accuracy was related to the degree of kinship of the affected relative, but not to age and gender of the counsellee, nor to the reason for referral or personal history of cancer. Age at diagnosis and multiple primary tumours were reported accurately in 97% and 94% of cases, respectively. In six out of 120 families verification data changed clinical genetic management, in five of these the genetic risk was reduced. Although verification of all reported cancer cases in a family remains the 'gold standard' for clinical as well as research purposes, verification of reports on breast cancer can be limited without seriously compromising medical decision making. In cases where verification is impossible because medical records are unavailable, findings from studies such as ours may help in interpreting family histories.

show abstract

Section: Introductionmentioning

confidence: 99%

Accuracy of family history of cancer: clinical genetic implications

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Studies examining the accuracy of patient-reported family histories indicate that the site of a cancer diagnosis in FDRs and SDRs is correctly reported in 78%-95% and 53%-67% of cases, respectively [18][19][20]. When considering only FDRs, the incidence of cancers in the study population aligned almost completely with the previously established cancer associations for BRCA mutations.…”

Section: Discussionmentioning

confidence: 53%

“…Furthermore, no decreased SIRs were observed in the population of only FDRs. Studies have suggested that underreporting of cancer is more common than overreporting of cancer in family histories [18,19,21,22]. This could provide an explanation for the number of decreased SIRs observed in the overall study population when SDRs were included in the analysis.…”

Section: Discussionmentioning

confidence: 97%

Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

Streff¹,

Profato

et al. 2016

The Oncologist

View full text Add to dashboard Cite

Background. Mutations in the BRCA1 and BRCA2 genes are associated with increased risk of breast, ovarian, and several other cancers. The purpose of the present study was to evaluate the incidence of cancer in first-and second-degree relatives of BRCA mutation carriers compared with the general population. Materials and Methods. A total of 1,086 pedigrees of BRCA mutation carriers was obtained from a prospectively maintained, internal review board-approved study of persons referred for clinical genetic counseling at the University of Texas MD Anderson Cancer Center. We identified 9,032 firstand second-degree relatives from 784 pedigrees that had demonstrated a clear indication of parental origin of mutation. Standardized incidence ratios (SIRs) were used to compare the observed incidence of 20 primary cancer sites to the expected incidence of each cancer based on the calculated riskestimates according to each subject's age, sex, and ethnicity.

show abstract

“…In this study, cancer diagnoses among relatives were not histologically confirmed. Love et al 39 estimated the accuracy of family cancer history reports and concluded that information on primary-site cancer among first-degree relatives was 83% accurate. The lack of data on relatives' ages may also have distorted the estimates, considering that subjects with older relatives would be expected to have more cancer in the family than would subjects with younger relatives.…”

Section: Resultsmentioning

confidence: 99%

Familial cancer aggregation and the risk of lung cancer

et al. 2002

View full text Add to dashboard Cite

CONTEXT: Around 90% of lung cancer worldwide is attributable to cigarette smoking, although less than 20% of cigarette smokers develop lung cancer. Other factors such as diet, chronic lung diseases, occupation and possibly environmental agents also contribute to this cancer. Genetic factors seem to play a role in lung cancer, but the precise characteristics influencing lung cancer susceptibility are not known, since genetic factors are easily obscured by the strong environmental determinants of lung cancer, particularly smoking. OBJECTIVE:To estimate the effect that cancer occurrence among first-degree relatives has on the risk of lung cancer. DESIGN:Hospital-based case-control study. SETTING:The metropolitan region of São Paulo, Brazil.PARTICIPANTS: 334 incident lung cancer cases and 578 controls matched by hospitals. MAIN MEASUREMENTS:By means of a structured questionnaire, cases and controls were interviewed about cancer occurrence in first-degree relatives, tobacco smoking, exposure to passive smoking, occupation, migration and socioeconomic status. Non-conditional logistic regression was used to calculate the risk of familial cancer aggregation, the effect of cancer in first-degree relatives and smoking in conjunction, and for controlling confounders. RESULTS:The adjusted odds ratio (OR) revealed a slight, but not statistically significant, excess risk of lung cancer for subjects with a history of lung cancer in relatives (OR 1.21; 95% confidence interval [CI] 0.50 -2.92). The same was found among those with a history of other tobacco-related cancers in relatives (OR 1.36; 95% CI 0.87 -2.14). A step gradient effect was observed regarding lung cancer risk, in accordance with increases in the number of pack-years of cigarette consumption. An interaction between familial cancer aggregation and tobacco smoking was detected. CONCLUSIONS:A mildly elevated risk of lung cancer among persons with a positive history of lung and other tobacco-related cancers was observed. The finding of an interaction between the variables of familial cancer aggregation and smoking suggests that familial cancer aggregation could be considered as a marker of susceptibility, increasing the risk of lung cancer among smokers. These results improve our knowledge of lung carcinogenesis and can guide future cancer genetic studies.

show abstract

The accuracy of patient reports of a family history of cancer

Cited by 227 publications

References 7 publications

Accuracy of family history of cancer: clinical genetic implications

Accuracy of family history of cancer: clinical genetic implications

Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers

Familial cancer aggregation and the risk of lung cancer

Contact Info

Product

Resources

About